In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led
to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors …

Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

The balance of programmed death-1 (PD-1)-expressing CD8+ T cells and regulatory T
(Treg) cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 …

High expression of PD-L1 in tumor cells contributes to tumor immune evasion. However,
whether PD-L1 expression in tumor cells is regulated by the availability of nutrients is …

Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

The MYC proto-oncogenes encode a family of transcription factors that are among the most
commonly activated oncoproteins in human neoplasias. Indeed, MYC aberrations or …

Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Background Continual expression of PD-L1 in tumor cells is critical for tumor immune
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …

Genome editing holds great potential for cancer treatment due to the ability to precisely
inactivate or repair cancer-related genes. However, delivery of CRISPR/Cas to solid tumours …